Safety and Efficacy of MDL 28,574A in HIV-Infected Patients

This study focuses on understanding the safety and effectiveness of a drug called MDL 28,574A in treating patients with HIV infection. The HIV infection is at an early stage, either without symptoms or with mild symptoms. The study aims to find out how well the drug works when given alone and when combined with another HIV medication, zidovudine (AZT). By conducting this research, the study hopes to improve treatment options for HIV patients and address the challenges associated with managing this condition. During the study, participants receive fixed doses of MDL 28,574A, either by itself or in combination with AZT. The study then examines how the drug affects different demographic groups by looking at its pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body). This helps the researchers understand the safety and effectiveness of MDL 28,574A for various populations. Participants' health and response to treatment are closely monitored throughout the study.